Overview Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma Status: Completed Trial end date: 2014-03-01 Target enrollment: Participant gender: Summary The purpose of this study is: Phase1: To evaluate the safety and determine the recommended dose (RD) Phase2: To evaluate the efficacy Phase: Phase 1/Phase 2 Details Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.